Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Total Current Liabilities (2022 - 2026)

HeartSciences filings provide 5 years of Total Current Liabilities readings, the most recent being $4.3 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 19.53% to $4.3 million in Q1 2026 year-over-year; TTM through Jan 2026 was $4.3 million, a 19.53% increase, with the full-year FY2025 number at $3.7 million, up 111.4% from a year prior.
  • Total Current Liabilities hit $4.3 million in Q1 2026 for HeartSciences, up from $1.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $4.3 million in Q1 2026 to a low of $1.4 million in Q3 2024.
  • Median Total Current Liabilities over the past 5 years was $2.5 million (2023), compared with a mean of $2.6 million.
  • The widest YoY moves for Total Current Liabilities: up 123.02% in 2025, down 52.57% in 2025.
  • HeartSciences' Total Current Liabilities stood at $3.1 million in 2022, then grew by 12.5% to $3.5 million in 2023, then decreased by 6.47% to $3.3 million in 2024, then plummeted by 52.57% to $1.6 million in 2025, then soared by 172.53% to $4.3 million in 2026.
  • The last three reported values for Total Current Liabilities were $4.3 million (Q1 2026), $1.6 million (Q4 2025), and $3.0 million (Q3 2025) per Business Quant data.